Potential Molecular Targeted Therapy for Unresectable Hepatocellular Carcinoma
Hepatocellular carcinoma (HCC) is one of the most prevalent and lethal cancers, representing a serious worldwide health concern. The recurrence incidence of hepatocellular carcinoma (HCC) following surgery or ablation is as high as 70%. Thus, the clinical applicability of standard surgery and other...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-01-01
|
| Series: | Current Oncology |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1718-7729/30/2/105 |
| _version_ | 1797621562640171008 |
|---|---|
| author | Shashank Kumar Abhay Kumar Pandey |
| author_facet | Shashank Kumar Abhay Kumar Pandey |
| author_sort | Shashank Kumar |
| collection | DOAJ |
| description | Hepatocellular carcinoma (HCC) is one of the most prevalent and lethal cancers, representing a serious worldwide health concern. The recurrence incidence of hepatocellular carcinoma (HCC) following surgery or ablation is as high as 70%. Thus, the clinical applicability of standard surgery and other locoregional therapy to improve the outcomes of advanced HCC is restricted and far from ideal. The registered trials did not identify a treatment that prolonged recurrence-free survival, the primary outcome of the majority of research. Several investigator-initiated trials have demonstrated that various treatments extend patients’ recurrence-free or overall survival after curative therapies. In the past decade, targeted therapy has made significant strides in the treatment of advanced HCC. These targeted medicines produce antitumour effects via specific signals, such as anti-angiogenesis or advancement of the cell cycle. As a typical systemic treatment option, it significantly improves the prognosis of this fatal disease. In addition, the combination of targeted therapy with an immune checkpoint inhibitor is redefining the paradigm of advanced HCC treatment. In this review, we focused on the role of approved targeted medicines and potential therapeutic targets in unresectable HCC. |
| first_indexed | 2024-03-11T08:57:47Z |
| format | Article |
| id | doaj.art-454fa7c53ad142a2a1a37dcf69270722 |
| institution | Directory Open Access Journal |
| issn | 1198-0052 1718-7729 |
| language | English |
| last_indexed | 2024-03-11T08:57:47Z |
| publishDate | 2023-01-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Current Oncology |
| spelling | doaj.art-454fa7c53ad142a2a1a37dcf692707222023-11-16T19:57:21ZengMDPI AGCurrent Oncology1198-00521718-77292023-01-013021363138010.3390/curroncol30020105Potential Molecular Targeted Therapy for Unresectable Hepatocellular CarcinomaShashank Kumar0Abhay Kumar Pandey1Molecular Signaling & Drug Discovery Laboratory, Department of Biochemistry, Central University of Punjab, Guddha, Bathinda 151401, Punjab, IndiaDepartment of Biochemistry, University of Allahabad, University Road, Prayagraj 211002, Uttar Pradesh, IndiaHepatocellular carcinoma (HCC) is one of the most prevalent and lethal cancers, representing a serious worldwide health concern. The recurrence incidence of hepatocellular carcinoma (HCC) following surgery or ablation is as high as 70%. Thus, the clinical applicability of standard surgery and other locoregional therapy to improve the outcomes of advanced HCC is restricted and far from ideal. The registered trials did not identify a treatment that prolonged recurrence-free survival, the primary outcome of the majority of research. Several investigator-initiated trials have demonstrated that various treatments extend patients’ recurrence-free or overall survival after curative therapies. In the past decade, targeted therapy has made significant strides in the treatment of advanced HCC. These targeted medicines produce antitumour effects via specific signals, such as anti-angiogenesis or advancement of the cell cycle. As a typical systemic treatment option, it significantly improves the prognosis of this fatal disease. In addition, the combination of targeted therapy with an immune checkpoint inhibitor is redefining the paradigm of advanced HCC treatment. In this review, we focused on the role of approved targeted medicines and potential therapeutic targets in unresectable HCC.https://www.mdpi.com/1718-7729/30/2/105liver cancersurvivalrecurrenceclinical trialtherapeutic target |
| spellingShingle | Shashank Kumar Abhay Kumar Pandey Potential Molecular Targeted Therapy for Unresectable Hepatocellular Carcinoma Current Oncology liver cancer survival recurrence clinical trial therapeutic target |
| title | Potential Molecular Targeted Therapy for Unresectable Hepatocellular Carcinoma |
| title_full | Potential Molecular Targeted Therapy for Unresectable Hepatocellular Carcinoma |
| title_fullStr | Potential Molecular Targeted Therapy for Unresectable Hepatocellular Carcinoma |
| title_full_unstemmed | Potential Molecular Targeted Therapy for Unresectable Hepatocellular Carcinoma |
| title_short | Potential Molecular Targeted Therapy for Unresectable Hepatocellular Carcinoma |
| title_sort | potential molecular targeted therapy for unresectable hepatocellular carcinoma |
| topic | liver cancer survival recurrence clinical trial therapeutic target |
| url | https://www.mdpi.com/1718-7729/30/2/105 |
| work_keys_str_mv | AT shashankkumar potentialmoleculartargetedtherapyforunresectablehepatocellularcarcinoma AT abhaykumarpandey potentialmoleculartargetedtherapyforunresectablehepatocellularcarcinoma |